Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4- (methylsulfonyl)benzamide), an orally bioavailable systemic hedgehog signalling pathway inhibitor

Xenobiotica

Volumn 39, Issue 11, 2009, Pages 850-861

  Wong, H ^a   Chen, J Z ^a   Chou, B ^a   Halladay, J S ^a   Kenny, J R ^a   La, H ^a   Marsters Jr , J C ^a   Plise, E ^a   Rudewicz, P J ^a   Robarge, K ^a   Shin, Y ^a   Wong, S ^a   Zhang, C ^a   Khojasteh, S C ^a  

^a GENENTECH INC   (United States)

Author keywords

Absorption; Allometry; Distribution; Hedgehog pathway inhibitor; Human prediction; Metabolism; Metabolism and excretion (ADME); Pharmacokinetics

Indexed keywords

2 CHLORO N [4 CHLORO 3 (PYRIDIN 2 YL)PHENYL] 4 (METHYLSULFONYL)BENZAMIDE; BENZAMIDE DERIVATIVE; BENZENE DERIVATIVE; CHLORINE DERIVATIVE; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; GDC 0449; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PYRIDINE DERIVATIVE; ROSIGLITAZONE; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG; WARFARIN;

ALLOMETRY; ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DISTRIBUTION VOLUME; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG OXIDATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; LIVER CELL; LIVER MICROSOME; MALE; MONKEY; MOUSE; NONHUMAN; PARTITION COEFFICIENT; RABBIT; RAT;

ADMINISTRATION, ORAL; ANILIDES; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; DRUG EVALUATION, PRECLINICAL; HEDGEHOG PROTEINS; HEPATOCYTES; HUMANS; INJECTIONS, INTRAVENOUS; MACACA FASCICULARIS; METABOLIC CLEARANCE RATE; MICE; MICROSOMES, LIVER; PYRIDINES; RABBITS; RATS; RATS, SPRAGUE-DAWLEY;

CANIS FAMILIARIS; ERINACEIDAE; MUS; RATTUS;

EID: 70350309505     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498250903180289     Document Type: Article

References (20)

1. Berman DM, Karhadkar SS, Maitra A, Montes De Oca R, Gerstenblith MR, Briggs K, Parker AR, Shimada Y, Eshleman JR, Watkins DN, Beachy PA. 2003. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425:846-851
2. Borzillo GV, Lippa B. 2005. The Hedgehog signaling pathway as a target for anticancer drug discovery. Curr Top Med Chem 5:147-157
3. Boxenbaum H. 1984. Interspecies pharmacokinetic scaling and the evolutionary- comparative paradigm. Drug Metab Rev 15:1071-1121
4. Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095
5. Feldmann G, Fendrich V, McGovern K, Bedja D, Bisht S, Alvarez H, Koorstra JB, Habbe N, Karikari C, Mullendore M, Gabrielson KL, Sharma R, Matsui W, Maitra A. 2008. An orally bioavailable smallmolecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol Cancer Ther 7:2725-2735
6. Gibaldi M, Perrier D. 1982. Pharmacokinetics. 2nd ed. New York, NY: Marcel Dekker.
7. Grace JE Jr, Wong H, Sinz M, Lentz K. 2008. Comparison of the kinetics of midazolam and dextromethorphan metabolism in chimpanzee, cynomolgus, marmoset, rhesus and human liver microsomes. Paper presented at the AAPS Annual Meeting, Atlanta, GA, USA, 16-20 November 2008.
8. Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, Isaacs JT, Berman DM, Beachy PA. 2004. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 431:707-712
9. Kumar SK, Roy I, Anchoori RK, Fazli S, Maitra A, Beachy PA, Khan SR. 2008. Targeted inhibition of Hedgehog signaling by cyclopamine prodrugs for advanced prostate cancer. Bioorg Med Chem 16:2764-2768
10. Lin JH. 1998. Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab Disp 26:1202-1212
11. Lipinski RJ, Hutson PR, Hannam PW, Nydza RJ, Washington IM, Moore RW, Girdaukas GG, Peterson RE, Bushman W. 2008. Dose- and route-dependent teratogenicity, toxicity, and pharamcokinetic profiles of the Hedgehog signaling anatagonist cyclopamine in the mouse. Tox Sci 104:189-197
12. Pasca di Magliano M, Hebrok M. 2003. Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer 3:903-911
13. Romer J, Curran T. 2005. Targeting medulloblastoma: small-molecule inhibitors of the Sonic Hedgehog pathway as potential cancer therapeutics. Cancer Res 65:4975-4978
14. Rubin LL, de Sauvage FJ. 2006. Targeting the Hedgehog pathway in cancer. Nat Rev Drug Disc 5:1026-1033
15. Segel IH. 1993. Enzyme kinetics. New York, NY: Wiley.
16. Smith PL. 1996. Methods for evaluating intestinal permeability and metabolism in vitro. In: Borchardt RT, Smith PL, Wilson G, editors. Models for assessing drug absorption and metabolism. New York, NY: Plenum. p. 13-34.
17. Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernández-del Castillo C, Yajnik V, Antoniu B, McMahon M, Warshaw AL, Hebrok M. 2003. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425:851-856
18. Tremblay MR, Nevalainen M, Nair SJ, Porter JR, Castro AC, Behnke ML, Yu LC, Hagel M, White K, Faia K, Grenier L, Campbell MJ, Cushing J, Woodward CN, Hoyt J, Foley MA, Read MA,Sydor JR, Tong JK, Palombella VJ, McGovern K, Adams J. 2008. Semisynthetic cyclopamine analogues as potent and orally bioavailable Hedgehog pathway antagonists. J Med Chem 51:6646-6649
19. Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, Baylin SB. 2003. Hedgehog signaling within airway epithelial progenitors and in small-cell lung cancer. Nature 422:313-317
20. Zhang Y, Laterra J, Pomper MG. 2009. Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/ Pgp. Neoplasia 11:96-101.